For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
0
references
 Top references
cited by
4
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The goal of this study was to estimate the relative efficacy of acalabrutinib (monotherapy and in combination with obinutuzumab) compared with standard frontline treatments for chronic lymphocytic leukemia (CLL) in fludarabine-ineligible patients, through a network meta-analysis (NMA).

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Clin Ther
          Title: Clinical therapeutics
          Publisher: Elsevier BV
          ISSN (Electronic): 1879-114X
          ISSN (Print): 0149-2918
          Publication date (Electronic): October 2020
          Volume: 42
          Issue: 10
          Affiliations
          [1 ] Department of Medical Oncology, Dana-Farber Cancer Institute, Wayland, MA, USA.
          [2 ] AstraZeneca, Gaithersburg, MD, USA. Electronic address: catherine.waweru@astrazeneca.com.
          [3 ] Amaris Consulting, Health Economics and Market Access, Toronto, Ontario, Canada.
          [4 ] Amaris Consulting, Health Economics and Market Access, London, United Kingdom.
          [5 ] Parexel International, Punjab, India.
          [6 ] AstraZeneca, Gaithersburg, MD, USA; Acerta Pharma (affiliated with AstraZeneca), 121 Oyster Point Blvd, South San Francisco, CA 94080, United States.
          [7 ] Sorbonne University, Haematology Department, Pitie Salpêtrière Hospital APHP, Paris Cedex, France.
          Article
          Publisher Item ID: S0149-2918(20)30423-9
          DOI: 10.1016/j.clinthera.2020.08.017
          PubMed ID: 33032842
          SO-VID: 838c4792-709f-42ec-8db1-b59bc57f6782
          Copyright © Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
          History

          Keywords: acalabrutinib,chronic lymphocytic leukemia,frontline treatment,network meta-analysis
          Data availability:
          Keywords: acalabrutinib, chronic lymphocytic leukemia, frontline treatment, network meta-analysis

          Comments

          Comment on this article